mhurhangee/patent-ind-claim-en huggingface dataset:
An in vitro method of detecting a plasmodium infection in a blood sample, the method comprising: staining the blood sample with at least first and second dyes, the first dye being a fluorescent dye that predominantly stains DNA, and the second dye being a fluorescent dye that stains at least one other cellular component that is different from DNA; acquiring one or more optical images of the sample; within the one or more optical images, identifying at least a first stained area that is stained by the first dye, and at least one other stained area that is stained by the second dye; and identifying the blood sample as being infected with plasmodium, by identifying, within the one or more optical images, at least one of: a stained object comprising at least the first stained area, and the area of the first stained area being in the range of 0.2μm 2 to 20μm 2 ; a stained object comprising the first stained area and said at least one other stained area, the area of said at least one other stained area being in the range of 0.8μm 2 to 65μm 2 ; and a stained object comprising the first stained area and said at least one other stained area, and the area of the first stained area occupies between 12% and 60% of said at least one other stained area. staining the blood sample with at least first and second dyes, the first dye being a fluorescent dye that predominantly stains DNA, and the second dye being a fluorescent dye that stains at least one other cellular component that is different from DNA; acquiring one or more optical images of the sample; within the one or more optical images, identifying at least a first stained area that is stained by the first dye, and at least one other stained area that is stained by the second dye; and identifying the blood sample as being infected with plasmodium, by identifying, within the one or more optical images, at least one of: a stained object comprising at least the first stained area, and the area of the first stained area being in the range of 0.2μm 2 to 20μm 2 ; a stained object comprising the first stained area and said at least one other stained area, the area of said at least one other stained area being in the range of 0.8μm 2 to 65μm 2 ; and a stained object comprising the first stained area and said at least one other stained area, and the area of the first stained area occupies between 12% and 60% of said at least one other stained area. a stained object comprising at least the first stained area, and the area of the first stained area being in the range of 0.2μm 2 to 20μm 2 ; a stained object comprising the first stained area and said at least one other stained area, the area of said at least one other stained area being in the range of 0.8μm 2 to 65μm 2 ; and a stained object comprising the first stained area and said at least one other stained area, and the area of the first stained area occupies between 12% and 60% of said at least one other stained area.
A method performed by a communication device working on an unlicensed frequency band, comprising: determining a mapping relationship between multiple quality of service, QoS, priority classes and multiple Listen-Before-Talk, LBT, priority classes, wherein the multiple QoS priority classes are in one-to-one correspondence with multiple QoS requirements, wherein the mapping relationship comprises: mapping each QoS priority class only to one LBT priority class; and transmitting radio traffic based on the mapping relationship.
A method for preparing a powder coating composition comprising: a) mixing in an aqueous medium (i) a carboxylic acid functional polymer having a glass transition temperature of at least 50°C, with (ii) a polycarbodiimide having a glass transition temperature of at least 50°C; b) drying the mixture of (i) and (ii) to obtain solid particles; and c) grinding the solid particles to obtain a powder. a) mixing in an aqueous medium (i) a carboxylic acid functional polymer having a glass transition temperature of at least 50°C, with (ii) a polycarbodiimide having a glass transition temperature of at least 50°C; (i) a carboxylic acid functional polymer having a glass transition temperature of at least 50°C, with (ii) a polycarbodiimide having a glass transition temperature of at least 50°C; b) drying the mixture of (i) and (ii) to obtain solid particles; and c) grinding the solid particles to obtain a powder.
A medical device comprising processing circuitry configured to: receive an electrical signal sensed via a plurality of electrodes disposed on one or more leads implanted within an epidural space of a patient; determine, from the electrical signal, one or more cardiac features indicative of activity of a heart of the patient; and control, based on the one or more cardiac features, delivery of spinal cord stimulation (SCS) therapy to the patient, wherein to control, based on one or more cardiac features, delivery of the SCS therapy, the processing circuitry is configured to: determine that the one or more cardiac features are indicative of a change in pain experienced by the patient; and control, based on the determination that that the one or more cardiac features are indicative of the change in pain experienced by the patient, delivery of the SCS therapy, and wherein the one or more cardiac features comprise a heart rate variability (HRV) of the heart of the patient. receive an electrical signal sensed via a plurality of electrodes disposed on one or more leads implanted within an epidural space of a patient; determine, from the electrical signal, one or more cardiac features indicative of activity of a heart of the patient; and control, based on the one or more cardiac features, delivery of spinal cord stimulation (SCS) therapy to the patient, wherein to control, based on one or more cardiac features, delivery of the SCS therapy, the processing circuitry is configured to: determine that the one or more cardiac features are indicative of a change in pain experienced by the patient; and control, based on the determination that that the one or more cardiac features are indicative of the change in pain experienced by the patient, delivery of the SCS therapy, and determine that the one or more cardiac features are indicative of a change in pain experienced by the patient; and control, based on the determination that that the one or more cardiac features are indicative of the change in pain experienced by the patient, delivery of the SCS therapy, and wherein the one or more cardiac features comprise a heart rate variability (HRV) of the heart of the patient.
Motor vehicle clutch release bearing comprising a rotating ring and a fixed ring each provided with a rolling track forming between them a raceway in which rolling elements are arranged to guide the relative rotation of said rings, the rotating ring having a bearing surface for actuating the diaphragm of the clutch, said bearing surface extending inwardly in a substantially radial direction on the front side of the rolling track of the rotating ring , the rotating ring having a sealing bearing surface formed on the rear side of the rolling track , said sealing surface extending inwardly along a substantially radial direction while forming a reduced clearance (J) with a complementary bearing surface of the fixed ring , at least the rotation ring being made in one piece and said release bearing being characterized in that the fixed ring has a rear wall forming the complementary bearing surface and extending substantially axially and radially opposite that where the sealing bearing surface is arranged to form the reduced clearance (J), said reduced clearance (J) being formed at the interface of an inner edge of the sealing bearing surface and the complementary bearing surface of the inner ring .
The use of a compound of structural formula I which is of the stereochemical configuration: or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for inhibiting HCV NS5B polymerase, inhibiting HCV viral replication or treating HCV infection; wherein B is L is CH or N; E is N or CR 5 ; W is O or S; Y is H, C 1-10 alkylcarbonyl, P 3 O 9 H 4 , P 2 O 6 H 3 , or P(O)R 9 R 10 ; R 1 is C 2-4 alkenyl, C 2-4 alkynyl, or C 1-4 alkyl optionally substituted with amino, hydroxy, or 1 to 3 fluorine atoms and one of R 2 and R 3 is hydroxy or C 1-4 alkoxy and the other of R 2 and R 3 is selected from the group consisting of hydrogen, hydroxy, halogen, C 1-4 alkyl, optionally substituted with 1 to 3 fluorine atoms, C 1-10 alkoxy, optionally substituted with C 1-3 alkoxy or 1 to 3 fluorine atoms, C 2-6 alkenyloxy, C 1-4 alkylthio, C 1-8 alkylcarbonyloxy, aryloxycarbonyl, azido, amino, C 1-4 alkylamino, and di(C 1-4 alkyl)amino; R 4 and R 6 are each independently H, OH, SH, NH 2 , C 1-4 alkylamino, di(C 1-4 alkyl)amino, C 3-6 cycloalkylamino, halogen, C 1-4 alkyl, C 1-4 alkoxy, or CF 3 ; R5 is H, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-4 alkylamino, CF 3 , or halogen; R 12 and R 13 are each independently hydrogen, methyl, hydroxymethyl, or fluoromethyl; and R 9 and R 10 are each independently hydroxy, OCH 2 CH 2 SC(=O)C 1-4 alkyl, OCH 2 O(C=O)OC 1-4 alkyl, NHCHMeCO 2 Me, OCH(C 1-4 alkyl)O(C=O)C 1-4 alkyl, wherein the compound is administered in the form of a tablet or capsule containing at least 0.1 percent by weight of the compound. L is CH or N; E is N or CR 5 ; W is O or S; Y is H, C 1-10 alkylcarbonyl, P 3 O 9 H 4 , P 2 O 6 H 3 , or P(O)R 9 R 10 ; R 1 is C 2-4 alkenyl, C 2-4 alkynyl, or C 1-4 alkyl optionally substituted with amino, hydroxy, or 1 to 3 fluorine atoms and one of R 2 and R 3 is hydroxy or C 1-4 alkoxy and the other of R 2 and R 3 is selected from the group consisting of hydrogen, hydroxy, halogen, C 1-4 alkyl, optionally substituted with 1 to 3 fluorine atoms, C 1-10 alkoxy, optionally substituted with C 1-3 alkoxy or 1 to 3 fluorine atoms, C 2-6 alkenyloxy, C 1-4 alkylthio, C 1-8 alkylcarbonyloxy, aryloxycarbonyl, azido, amino, C 1-4 alkylamino, and di(C 1-4 alkyl)amino; hydrogen, hydroxy, halogen, C 1-4 alkyl, optionally substituted with 1 to 3 fluorine atoms, C 1-10 alkoxy, optionally substituted with C 1-3 alkoxy or 1 to 3 fluorine atoms, C 2-6 alkenyloxy, C 1-4 alkylthio, C 1-8 alkylcarbonyloxy, aryloxycarbonyl, azido, amino, C 1-4 alkylamino, and di(C 1-4 alkyl)amino; R 4 and R 6 are each independently H, OH, SH, NH 2 , C 1-4 alkylamino, di(C 1-4 alkyl)amino, C 3-6 cycloalkylamino, halogen, C 1-4 alkyl, C 1-4 alkoxy, or CF 3 ; R5 is H, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-4 alkylamino, CF 3 , or halogen; R 12 and R 13 are each independently hydrogen, methyl, hydroxymethyl, or fluoromethyl; and R 9 and R 10 are each independently hydroxy, OCH 2 CH 2 SC(=O)C 1-4 alkyl, OCH 2 O(C=O)OC 1-4 alkyl, NHCHMeCO 2 Me, OCH(C 1-4 alkyl)O(C=O)C 1-4 alkyl, wherein the compound is administered in the form of a tablet or capsule containing at least 0.1 percent by weight of the compound.
An unmanned underwater vehicle propulsion system comprising: a turbine engine including a mechanical output and a combustor connected to a partial admission axial turbine via a supersonic nozzle ; an electrical generator including a mechanical connection to the mechanical output, and an electrical input/output; at least one power bus connecting the electrical input/output to one of a motor drive and a motor ; a rechargeable energy storage system connected to the at least one power bus and configured to provide power to the power bus in at least a first mode and receive power from the power bus in a second mode; and a controller configured to control at least one of the electrical generator , the motor drive, the motor , and the rechargeable energy source ; wherein the controller includes a memory storing instructions for causing the propulsion system to repeatedly cycle between a turbine operation mode and a DC supply operation mode, and wherein transitioning from the DC supply operation to the turbine operation mode includes initiating turbine operations. a turbine engine including a mechanical output and a combustor connected to a partial admission axial turbine via a supersonic nozzle ; an electrical generator including a mechanical connection to the mechanical output, and an electrical input/output; at least one power bus connecting the electrical input/output to one of a motor drive and a motor ; a rechargeable energy storage system connected to the at least one power bus and configured to provide power to the power bus in at least a first mode and receive power from the power bus in a second mode; and a controller configured to control at least one of the electrical generator , the motor drive, the motor , and the rechargeable energy source ; wherein the controller includes a memory storing instructions for causing the propulsion system to repeatedly cycle between a turbine operation mode and a DC supply operation mode, and wherein transitioning from the DC supply operation to the turbine operation mode includes initiating turbine operations.
A pharmaceutical tablet composition comprising levodopa, carbidopa and entacapone or pharmaceutically acceptable salts or hydrates thereof and pharmaceutically acceptable excipient characterized in that ; carbidopa and levodopa are granulated together and entacapone is granulated separately with one or more pharmaceutically acceptable excipients by wet granulation method, wherein median particle size distribution d of entacapone or pharmaceutically acceptable salts or hydrates is about 2 μm volume equivalent when measured by the method of laser diffraction in a dry dispersion system.
An infiltration body for the production of rainwater storage units, wherein the infiltration body comprises at least one cavity, wherein the infiltration body comprises at least three lattice-like walls water-permeable in sections, wherein the infiltration body comprises a channel for collecting sediments and flushing, and wherein the channel comprises a bottom, wherein one wall is constituted as a ceiling and two walls as side walls of the infiltration body and wherein two sides of the infiltration body lying opposite one another are open, characterised in that the infiltration body is constituted in one piece, that the bottom of the channel is constituted in one piece with the infiltration body , and that the bottom of the channel is constituted as a moulded, closed, water-impermeable bottom trough . the infiltration body is constituted in one piece, that the bottom of the channel is constituted in one piece with the infiltration body , and that the bottom of the channel is constituted as a moulded, closed, water-impermeable bottom trough .
A transmitting apparatus comprising: a transmission-signal generating circuit configured to generate at least one of a first type of schedule element supporting an allocation including a primary channel (CH1) and a second type of schedule element supporting an allocation including a plurality of channels (CH1-CH3) and that is configured to generate a MAC frame including the generated first type of schedule element and/or second type of schedule element; and a transmitting circuit that is configured to transmit the MAC frame over the primary channel (CH1), wherein the transmission signal generating circuit is configured to, when the allocation including the plurality of channels includes the primary channel (CH1), generate the first type of schedule element including allocation time information regarding the allocation including the plurality of channels and generate the second type of schedule element including supplemental information to the generated first type of schedule element , and when the allocation over the plurality of channels does not include the primary channel (CH1), omit the generation of the first type of schedule element and generate the second type of schedule element including a Channel Allocation field containing complete allocation information regarding the allocation over the plurality of channels. a transmission-signal generating circuit configured to generate at least one of a first type of schedule element supporting an allocation including a primary channel (CH1) and a second type of schedule element supporting an allocation including a plurality of channels (CH1-CH3) and that is configured to generate a MAC frame including the generated first type of schedule element and/or second type of schedule element; and a transmitting circuit that is configured to transmit the MAC frame over the primary channel (CH1), wherein the transmission signal generating circuit is configured to, when the allocation including the plurality of channels includes the primary channel (CH1), generate the first type of schedule element including allocation time information regarding the allocation including the plurality of channels and generate the second type of schedule element including supplemental information to the generated first type of schedule element , and when the allocation over the plurality of channels does not include the primary channel (CH1), omit the generation of the first type of schedule element and generate the second type of schedule element including a Channel Allocation field containing complete allocation information regarding the allocation over the plurality of channels.
A method of securing an electrical terminal within a connector body , said method comprising: a) providing the connector body defining a longitudinal terminal cavity therethrough; b) providing the electrical terminal , wherein the electrical terminal includes a first connection portion configured to attach the electrical terminal to a first conductor, a second connection portion configured to interconnect with a second conductor, and a transition portion intermediate the first connection portion and the second connection portion ; c) disposing the electrical terminal within the terminal cavity ; and d) deforming a portion of an outer surface of the connector body to fabricate a protrusion that projects from an inner surface of the connector body into the terminal cavity intermediate the first connection portion and the second connection portion , thereby securing the electrical terminal within the terminal cavity , characterized in that the thickness of a section of the connector body wall between the outer surface and the inner surface is reduced or thinned relative to the surrounding portion of the connector body wall prior to forming the protrusion , wherein the protrusion is formed by pressing the outer surface of the section of the connector body wall toward the inner surface of the terminal cavity using a generally cylindrical probe with an end contacting the outer surface having a generally flat central section concentrically surrounded by a compound curved section having a convex-concave-convex profile. a) providing the connector body defining a longitudinal terminal cavity therethrough; b) providing the electrical terminal , wherein the electrical terminal includes a first connection portion configured to attach the electrical terminal to a first conductor, a second connection portion configured to interconnect with a second conductor, and a transition portion intermediate the first connection portion and the second connection portion ; c) disposing the electrical terminal within the terminal cavity ; and d) deforming a portion of an outer surface of the connector body to fabricate a protrusion that projects from an inner surface of the connector body into the terminal cavity intermediate the first connection portion and the second connection portion , thereby securing the electrical terminal within the terminal cavity , characterized in that the thickness of a section of the connector body wall between the outer surface and the inner surface is reduced or thinned relative to the surrounding portion of the connector body wall prior to forming the protrusion , wherein the protrusion is formed by pressing the outer surface of the section of the connector body wall toward the inner surface of the terminal cavity using a generally cylindrical probe with an end contacting the outer surface having a generally flat central section concentrically surrounded by a compound curved section having a convex-concave-convex profile.
A liquid crystal display comprising: a chassis assembly ; a liquid crystal panel arranged to display an image; a light guide plate arranged to guide light to the liquid crystal panel; an LED module movable relative to the chassis assembly, the LED module comprising a printed circuit board disposed below the light guide plate, a plurality of LEDs mounted vertically on the printed circuit board arranged to emit light onto a side surface of the light guide plate, and a contact member , characterized in that the contact member is connected to the printed circuit board, the contact member being arranged to come into contact with the side surface of the light guide plate; and an elastic member arranged to elastically support the LED module; wherein the contact member is provided separately from and coupled to the printed circuit board ; and wherein the printed circuit board is formed with a fixing groove , and the contact member is arranged to be fitted into the fixing groove. a chassis assembly ; a liquid crystal panel arranged to display an image; a light guide plate arranged to guide light to the liquid crystal panel; an LED module movable relative to the chassis assembly, the LED module comprising a printed circuit board disposed below the light guide plate, a plurality of LEDs mounted vertically on the printed circuit board arranged to emit light onto a side surface of the light guide plate, and a contact member , characterized in that the contact member is connected to the printed circuit board, the contact member being arranged to come into contact with the side surface of the light guide plate; and an elastic member arranged to elastically support the LED module; wherein the contact member is provided separately from and coupled to the printed circuit board ; and wherein the printed circuit board is formed with a fixing groove , and the contact member is arranged to be fitted into the fixing groove.